Novelmed Therapeutics Inc
Small-molecule selective inhibitor of the alternative complement pathway for treating paroxysmal nocturnal hemoglobinuria
- Sector
- Biotech
- Headquarters
- Cleveland, OH
- Total capital
- $6.9M
- Federal grants
- $6.9M
- 8 awards · 2015–2021
- Rank in peer group#339 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 28 pending · first 2016
- Rank in peer group#23 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Disease Modifying Treatment for Hemolytic Disorders$533K
- Federal grantHealth and Human S · Phase II · Disease Modifying Treatment for Hemolytic Disorders$533K
- Federal grantHealth and Human S · Phase II · Treatment of Complement-Mediated Myelitis$300K
- Federal grantHealth and Human S · Phase II · Preclinical and Clinical Evaluation of Humanized NM9405$1.3M
- Federal grantHealth and Human S · Phase II · Single Therapy for Wet AMD & Geographic Atrophy$39K
- Federal grantHealth and Human S · Phase II · Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis$602K
- Federal grantHealth and Human S · Phase II · Preclinical and Clinical Evaluation of Humanized NM9405$1.2M
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase II · Preclinical and Clinical Evaluation of Humanized NM$2.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#23 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 12 granted of 40- PendingMonospecific And Bispecific Antibodies And Antigen Binding Fragments ThereofUSPTOApplication 18663175
- GrantedMonospecific And Bispecific Antibodies And Antigen Binding Fragments ThereofUSPTOUS 11,981,727
- GrantedMETHODS OF TREATING HEMOLYTIC DISORDERS COMPRISING ADMINISTERING AN ANTI-C3b ANTIBODYUSPTOUS 10,858,420
Show all 40 patent records
- Monospecific And Bispecific Antibodies And Antigen Binding Fragments ThereofFeb 6, 2025 · Application 18663175Pending
- Monospecific And Bispecific Antibodies And Antigen Binding Fragments ThereofMay 14, 2024 · US 11,981,727Granted
- METHODS OF TREATING HEMOLYTIC DISORDERS COMPRISING ADMINISTERING AN ANTI-C3b ANTIBODYDec 8, 2020 · US 10,858,420Granted
- Aglycosylated Anti-properdin AntibodiesJul 14, 2020 · US 10,711,056Granted
- Methods Of Treating Ocular DiseasesJun 30, 2020 · US 10,696,740Granted
- Methods Of Treating Ocular DiseasesJan 22, 2019 · US 10,183,989Granted
- ANTI-FACTOR Bb ANTIBODIESNov 20, 2018 · US 10,131,706Granted
- METHODS OF TREATING HEMOLYTIC DISORDERS COMPRISING ADMINISTERING ANTI-Bb ANTIBODIESJun 5, 2018 · US 9,988,441Granted
- Methods Of Treating A Hemolytic Disorder Comprising Administering Anti-properdin AntibodiesMar 27, 2018 · US 9,926,366Granted
- Formulation Of Aglycosylated Therapeutic AntibodiesJan 4, 2018 · Application 15541057Pending
- Neo Antibodies For Diagnostic Imaging Of Tissue InjuryNov 14, 2017 · US 9,816,999Granted
- Anti-properdin AntibodiesJun 13, 2017 · US 9,676,842Granted
- Methods And Compositions For Inhibiting Cellular Proliferation And Surgical AdhesionFeb 14, 2017 · US 9,566,297Granted
- AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOFNov 17, 2016 · Application 15012457Pending
- AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOFNov 17, 2016 · Application 15013431Pending
- Method Of Inhibiting Complement Activation With Human Anti-factor C3 Antibodies And Uses ThereofAug 25, 2016 · Application 14949566Pending
- Alternative Pathway Specific Antibodies For Treating ArthritisJul 21, 2016 · Application 14863301Pending
- HUMANIZED ANTI-FACTOR C3b ANTIBODIES AND USES THEREOFJan 26, 2016 · US 9,243,060Granted
- Method For Treating Inflammatory ConditionsAug 6, 2015 · Application 14657430Pending
- Humanized And Chimeric Anti-properdin AntibodiesJul 3, 2014 · Application 14195458Pending
- Anti-properdin AntibodiesMay 8, 2014 · Application 13849092Pending
- Aglycosylated Human Antibody And Fusion Protein And Uses ThereofApplication PCTUS2012072142Pending
- Neoantibodies For Diagnosing Tissue InjuryApplication PCTUS2011062418Pending
- Humanized And Chimeric Anti-properdin AntibodiesApplication PCTUS2011027964Pending
- A Method For Inhibiting Alternative Pathway Mediated Disorders With Anti-properdin Antibodies That Inhibit C5 Interactions With ProperdinApplication PCTUS2011026841Pending
- Methods And Compositions For Inhibiting Cellular Proliferation And Surgical AdhesionApplication PCTUS2010024452Pending
- Method Of Treating Ischemia Reperfusion InjuryApplication PCTUS2009064572Pending
- Device And Method For Inhibiting Complement ActivationApplication PCTUS2009056524Pending
- Method For Treating Inflammatory ConditionsApplication PCTUS2009045969Pending
- Inhibition Of Complement And Cellular ActivationApplication PCTUS2008074779Pending
- Method Of Inhibiting Complement Activation With Factor Bb Specific Antibodies And Use ThereofApplication PCTUS2008074489Pending
- Methods Of Treating Inflammatory Conditions With Adrenergic AntagonistsApplication PCTUS2008074212Pending
- Anti-properdin AntibodiesApplication PCTUS2008068530Pending
- Methods And Compositions Of Inhibiting Complement And Cellular Activation With Dextran SulfateApplication PCTUS2008061423Pending
- Method Of Inhibiting Complement Activation With Human Anti-factor C3 Antibodies And Use ThereofApplication PCTUS2008057468Pending
- Method Of Inhibiting Coagulation Activation With Human Anti-factor Va Antibodies And Use ThereofApplication PCTUS2007081388Pending
- Humanized And Chimeric Anti-factor C3 Antibodies And Uses ThereofApplication 14994993Pending
- HUMANIZED AND CHIMERIC ANTI-FACTOR Bb ANTIBODIES AND USES THEREOFApplication 14995003Pending
- Formulation Of Aglycosylated Therapeutic AntibodiesApplication PCTUS2015068327Pending
- Aglycosylated Anti-bb Antibodies And Uses ThereofApplication PCTUS2017015865Pending
Related companies, and why
- GRUTHAN BIOSCIENCE LLCSimilar federal contract value in Biotech · null in contracts
- ALZARROK BIO LLCSimilar federal contract value in Biotech · null in contracts
- CRYSTAL BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- SAB Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Atsena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RNA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .